Home / Business and Economy / Sun Pharma Eyes Organon Acquisition: A $13 Billion Power Play
Sun Pharma Eyes Organon Acquisition: A $13 Billion Power Play
24 Apr
Summary
- Sun Pharma offers $13 billion for US-based Organon & Co.
- Acquisition aims to transform Sun Pharma into a global drug powerhouse.
- Financing is secured with $12 billion from JP Morgan, MUFG, and Citi.
Sun Pharmaceutical has submitted a binding offer of $13 billion to acquire US-based Organon & Co, signaling its most significant strategic move to date. This ambitious bid aims to transform the Indian generics leader into a global powerhouse in branded and innovative drug manufacturing.
The all-cash offer is fully financed by JP Morgan, MUFG, and Citi, totaling $12 billion, with an additional $3.2 billion from Sun Pharma's balance sheet. If successful, Organon would be merged with Sun Pharma, though Organon shareholders would not receive Sun Pharma shares.
Organon, specializing in women's health and biosimilars, ended 2025 with $8.64 billion in debt. Buyers will need to refinance this debt, a key component of Sun Pharma's financing plan. The acquisition aims to bolster Sun Pharma's portfolio, particularly in areas like women's health and biosimilars.
Analysts have mixed views, with some seeing it as a positive strategic move for Organon and others concerned about Sun Pharma's capital allocation and increased leverage.
